12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Inclusion Criteria: * Female patients aged 18 years or older. * Belonging to the Asian race and specifically to the Chinese, Indian and Korean ethnicity. * Clinical diagnosis of IBS-D according to the following symptoms, based on Rome III modular questionnaire criteria: 1. Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics: * improvement with defecation * onset associated with a change in the frequency of stool * onset associated with a change in form (appearance) of stool. 2. Symptom-onset at least 6 months prior to diagnosis. 3. Loose or watery stools at least 25% of the time in the last 3 months AND hard or lumpy stools less than 25% of the time in the last 3 months. 4. Additional criterion: More than 3 bowel movements per day at least 25% of the time in the last 3 months. * For patients older than 50 years OR patients with a positive family history of colorectal cancer: Normal results from colonoscopy/flexible sigmoidoscopy performed within the last 5 years. * For patients aged 65 years or older: Absence of ischaemic colitis, microscopy colitis or any other organic gastrointestinal disease as evidenced by the results of a colonoscopy/flexible sigmoidoscopy with biopsy performed within 6 months. * For women of childbearing potential: Use of a highly effective contraceptive method with a failure rate \<1% per year throughout the entire study period. * Physical examination without clinically relevant abnormalities during screening. * No clinically relevant abnormalities in 12-Lead ECG or in laboratory findings. * Mentally competent, able to give written informed consent, and compliant to undergo all visits and procedures. * Unrestricted access to a touch-tone telephone. * Willingness to refrain from using loperamide within 3 days prior to run-in visit and during the run-in period. Additional criteria at randomisation: * During both weeks of the run-in period: 1. A weekly average of worst abdominal pain in the past 24 hours with a score of ≥3.0 on a 0 to 10 point scale. 2. At least one bowel movement on each day. 3. A weekly average of at least 3 bowel movements per day. 4. At least one stool with a consistency of Type 6 or Type 7 according to the Bristol Stool Scale (BSS) on at least 2 days per week. 5. Less than 2 bowel movements with a consistency of Type 1 or Type 2 according to the BSS per week. * Adequate compliance with the e-diary recording procedure defined as at least 11 of 14 days (≥75%) of the nominal daily data entry. Exclusion Criteria: * Male gender. * Diagnosis of IBS with a subtype of constipation, mixed IBS, or un-subtyped IBS. * Colonic or major abdominal surgery, any other major abdominal surgery or elective major surgery planned or expected during the study. * History of organic GI abnormalities, inflammatory bowel diseases, complicated diverticulosis, ischaemic colitis, microscopic colitis. * History of pancreatitis, active biliary duct disease, cholecystitis or symptomatic gallbladder stone disease in the previous 6 months. * History of gluten enteropathy or lactose intolerance. * Current or previous diagnosis of neoplasia. * History of endometriosis. * History of positive tests for ova or parasites, or clostridium difficile toxin or occult blood in the stool in the previous 6 months. * History of human immunodeficiency virus infection. * History of major cardiovascular events in the previous 6 months. * Uncontrolled hypertension, insulin-dependent diabetes mellitus or abnormal thyroid function. * Major psychiatric or neurological disorders or unstable medical condition which may compromise the efficacy and safety assessments. * Evidence of clinically significant hepatic disease, severe renal insufficiency or anemia. * Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2 months. * Use of prohibited concomitant medication within the previous month such as antibiotics, antimuscarinic drugs, drugs enhancing GI motility and analgesics. * Pregnancy or breastfeeding. * Inability to understand or collaborate throughout the study. * Participation in other clinical studies in the previous 4 weeks or concomitant enrollment in a clinical study. * Any condition that would compromise the well-being of the patient.